Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
J&J's nipocalimab shows promise in Phase II Sjögren's disease trial
Johnson & Johnson's Phase II DAHLIAS study of nipocalimab, an FcRn blocker, showed promising results in treating moderate-to-severe Sjögren’s disease, meeting primary and secondary endpoints, with significant improvements in ClinESSDAI scores and symptom relief.
Medical Devices Applying for Outpatient Medicare Supplemental Payments
CMS approved 40% of TPTP applications, including all FDA-designated breakthrough devices. Approved devices often lacked generalizability to Medicare beneficiaries, used surrogate markers, or did not meet all primary end points. Strengthening premarket clinical evidence requirements could improve clinical decision-making and care for Medicare beneficiaries.
CHMP recommends RYBREVANT® (amivantamab) in combination
Amivantamab plus lazertinib may set new standard for first-line treatment of advanced NSCLC with EGFR ex19del or L858R mutations, reducing progression risk by 30% vs. osimertinib in MARIPOSA study.
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
OS Therapies completed Phase 2b trial for OST-HER2 in osteosarcoma, expecting topline data in Dec 2024. OST-HER2, an immunotherapy targeting HER2, aims to prevent metastasis and increase survival. The company anticipates revenue from FDA approval and licensing rights.
J&J MedTech Advances into Surgical Robotics with Ottava Clinical Trials
Johnson & Johnson’s MedTech division received IDE approval for its Ottava robotic surgical system, enabling clinical trials in the U.S. Ottava features four low-profile robotic arms integrated into the operating table and a 'twin motion' feature for enhanced surgical precision and efficiency, positioning it as a competitor in the $8.6 billion surgical robotics market.
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG
Nipocalimab, an FcRn blocker, showed significant improvements in disease activity scores and IgG reductions in adults with moderate-to-severe Sjögren's disease after 24 weeks of treatment, according to the Phase 2 DAHLIAS study. The FDA granted Breakthrough Therapy Designation for nipocalimab based on these results.
Related Clinical Trials:
Positive Clinical Trial Results For Generative AI-Designed Drug
Insilico Medicine announced results from a clinical trial of ISM001-055, designed using generative AI to treat idiopathic pulmonary fibrosis, showing improvements in lung function and quality of life. Enveda began clinical trials of ENV-294, an oral inflammatory agent for atopic dermatitis, derived from natural compounds identified using AI. Various healthcare updates include FDA approvals, licensing agreements, and collaborations in drug discovery and treatment development.
J&J seek approval for first drug to treat high-risk smoldering myeloma
Johnson & Johnson applied to FDA and EMA for DARAZALEX FASPRO approval as monotherapy for high-risk smoldering multiple myeloma. If approved, it would be the first treatment for this condition, based on AQUILA study data to be presented at 2024 ASH annual meeting.
Can Canada's psychedelic drug developers shake off the sector's bad trip?
Cybin Inc. and MindMed Inc. plan to start phase 3 trials for psilocybin and LSD treatments in 2023, aiming for 2026 results. Despite recent setbacks, including FDA rejections and data issues, both companies remain optimistic, supported by FDA approvals and cautious analyst optimism.
TRex Bio raises $84M to compete in crowded immune drug field
TRex Bio raises $84M in Series B to advance immune drug research, including pushing TRB-061 into Phase 1 trials for atopic dermatitis and ulcerative colitis. The company's technology focuses on activating regulatory T cells to treat autoimmune conditions, with partnerships including Eli Lilly and Johnson & Johnson.
© Copyright 2024. All Rights Reserved by MedPath